Service & Quality
The Bioanalytical Services Unit provides liquid chromatographic-mass spectrometric (LC-MS/MS) and ligand binding analysis (LBA) to enable IND, NDA, BLA and ANDA packages. Our diverse discovery, preclinical and clinical bioanalytical strategies are fully integrated with other services at the Laboratory Testing Division, which enables us to carry your compound from discovery through clinical phases for increased efficiency and an accelerated timeline.
+ Discovery rapid turnaround bioanalysis
+ Preclinical bioanalysis using qualified and validated methods
+ Clinical bioanalysis using qualified and validated assays
Dedicated Global Facilities
Operating out of four state-of-the-art facilities throughout Asia and North America, the Bioanalytical Services Unit houses the largest bioanalytical laboratory in Asia. Our regional flexibility and worldwide expertise allow us to fully support our global drug discovery and development customers with end-to-end bioanalytical solutions to meet their varying needs.
Operations & Compliance
Under the authority of quality assurance teams skilled in global regulatory guidelines and GLP requirements, the Bioanalytical Services Unit is fully committed to the integrity of its scientific data, equipment and infrastructure in accordance with WuXi’s established quality processes.
Track Record of Success
Within the Bioanalytical Services Unit, we have the human capital, financial strength and global capacity to handle your project in its entirety, having supported thousands of global clinical trials to date and maintaining preferred vendor status with 6 of the top 20 global pharmaceutical companies.